Abstract:Purpose/Objective(s) Human-papilloma virus (HPV)-positive oropharyngeal cancer (OPC) is a potentially curable disease with a rising incidence in the United States. Despite improved radiation therapy (RT) techniques, toxicities remain a concern. Adaptive RT (ART) can reduce radiation to organs-at-risk (OARs) without sacrificing tumoricidal dose to target volumes, but there are barriers to routine implementation. These include (1) technical barriers to ART and (2) timing of ART for shrinking tumor volumes or changes in body contours (such as weight loss or contracture of OARs). Magnetic resonance (MR)-Linacs allow for frequent, online, and standardized plan adaption, made possible by improved visualization of tumors and OARs as well as an integrated planning system. This study aims to: (1) develop an ART workflow protocol using an online adapt-to-shape approach on our MR-Linac while (2) identifying barriers to performance (such as treatment times and the influence to quality of life) and (3) characterizing quantitative imaging biomarkers during RT. Materials/Methods Sixteen eligible participants with non-metastatic HPV+ OPC will be enrolled. All participants will undergo simulation on our institution's MR-Linac. Participants will receive concurrent chemoRT with a dose prescription of 70 Gy in 35 fractions on the MR-Linac. ART planning will occur every 5th fraction of RT (i.e. the 6th, 11th, 16th, 21st, 26th, and 31st fractions). At 3-months follow-up, participants will undergo another MRI scan on the MR-Linac. The primary endpoint is to assess the accuracy of ART by (1) calculating the percent difference between initial and weekly ART plans and (2) confirming accuracy of deformable imaging registration. Secondary endpoints include (1) treatment times, calculated from guidelines set by the MR-Linac Consortium Head and Neck Tumor Site, as well as (2) quality of life measurements using study questionnaires (i.e. EORTC QLQs Core 30 and H&N43) at all study timepoints. As an exploratory endpoint, quantitative imaging biomarkers of tumor and nodal volume regression will be descriptively characterized. Results This study is a trial-in-progress and has not reached pre-specified endpoints for analysis. Conclusion MR-Linacs are underutilized in the treatment of OPC patients, despite previous validation of clinically acceptable head and neck RT plans. For OPC patients, replanning is often static (i.e. at one timepoint), offline, and limited in standardization. This work will help clarify the role of MR-guided ART in HPV+ OPC: its feasibility, quality, and overall patient experience.

Preliminary experience using MR-guided adaptive radiotherapy in head and neck cancer

Clinical Experience with an Offline ART Head and Neck Program: Dosimetric Benefits and Opportunities for Patient Selection

MR-Guided Adaptive Radiotherapy for OAR Sparing in Head and Neck Cancers

In silico evaluation and feasibility of near margin-less head and neck daily adaptive radiotherapy

MR-guided stereotactic radiation therapy for head and neck cancers

A Retrospective Study on the Investigation of Potential Clinical Benefits of Online Adaptive Proton Therapy for Head and Neck Cancer

Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer

A retrospective study on the investigation of potential dosimetric benefits of online adaptive proton therapy for head and neck cancer

Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT

Magnetic resonance guided adaptive post prostatectomy radiotherapy: Accumulated dose comparison of different workflows

Estimating Potential Benefits of Online Adaptive Proton Therapy for Head-and-Neck Cancer: A Retrospective Study.

Clinical acceptance and dosimetric impact of automatically delineated elective target and organs at risk for head and neck MR-Linac patients

Does adaptive radiotherapy for head and neck cancer favorably impact dosimetric, clinical, and toxicity outcomes?: A review

Target Definition in MR-Guided Adaptive Radiotherapy for Head and Neck Cancer

Feasibility of Adaptive Radiation Therapy for Human-Papilloma Virus-Positive Oropharyngeal Cancer Patients Using MR-Guided RT

Technical Development and In Silico Implementation of SyntheticMR in Head and Neck Adaptive Radiation Therapy: A Prospective R-IDEAL Stage 0/1 Technology Development Report

Transition of Online Adaptive Stereotactic Radiotherapy for Pancreatic Cancer From Magnetic Resonance-Guided Linear Accelerator (MR-Linac) to State-of-the-Art Cone-Beam Computed Tomography (CBCT)

Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist's point of view

Forecasting patient-specific dosimetric benefit from daily online adaptive radiotherapy for cervical cancer

Weekly assessment of volumetric and dosimetric changes during volumetric modulated arc therapy of locally advanced head and neck carcinoma: Implications for adaptive radiation therapy—A prospective study

Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance–Guided Radiotherapy